NEOSPORIN EYE-EAR SOLUTION DIN 00694371
Health Canada record
| Active ingredient(s) | GRAMICIDIN 0.025 MG; POLYMYXIN B (POLYMYXIN B SULFATE) 10000 UNIT; NEOMYCIN (NEOMYCIN SULFATE) 1.75 MG |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic; Otic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S03AA30 ANTIINFECTIVES, COMBINATIONS |
| Original market date | 31-Dec-1987 |
| Current status date | 21-Nov-2006 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GRAMICIDIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02208288 | ANTIBIOTIC CREAM | TECHNILAB PHARMA INC. | Cream | GRAMICIDIN 0.25 MG; POLYMYXIN B SULFATE 10000 UNIT | Cancelled Post Market |
| 02457512 | ANTIBIOTIC DROPS | SANDOZ CANADA INCORPORATED | Solution | GRAMICIDIN 0.025 MG; POLYMYXIN B SULFATE 10000 UNIT | Cancelled Post Market |
International API supply for GRAMICIDIN
1 valid EDQM Certificates of Suitability from 1 holders. 1 active FDA Drug Master Files.
Request a quote for NEOSPORIN EYE-EAR SOLUTION